

# The use of capillary electrophoresis for studying the *in vitro* glucuronidation of 7-hydroxycoumarin

Declan P. Bogan, Anthony J. Killard, and Richard O'Kennedy

*School of Biological Sciences, Dublin City University, Dublin, Ireland*

**Correspondence:** *Dr. Richard O'Kennedy, School of Biological Sciences, Dublin City University, Dublin 9, Ireland*

## Abstract

An assay, utilizing CE, has been developed for studying the *in vitro* metabolism of 7-hydroxycoumarin to 7-hydroxycoumarin-glucuronide. A reaction mixture containing a crude preparation of bovine uridine diphosphate (UDP) glucuronyl transferase (UDPGT) and the substrates uridine diphosphate glucuronic acid (UDPGA) and 7-hydroxycoumarin was prepared. Aliquots were removed from the reaction mixture at specific time intervals and analyzed on a 57-cm untreated silica capillary for the presence of 7-hydroxycoumarin-glucuronide. Samples were electrophoresed in a 100 mM phosphate/11 mM deoxycholic acid (sodium salt)/acetonitrile electrolyte buffer, pH 7.0, at 30 kV, with detection at 320 nm. The method allowed the determination of 7-hydroxycoumarin-glucuronide without sample cleanup, with a limit of detection of 2 µg/mL, and a linear detection range of 0 µg/mL to 100 µg/mL. The 7-hydroxycoumarin-glucuronide concentrations were calculated from calibration curves of standards prepared in enzyme solution. The initial rate of production of 7-hydroxycoumarin-glucuronide, in the first 70 min, was  $3.1 \pm 0.13$  nmol/mL/min/mg protein. The method was fast and reliable with percentage relative standard deviations for concentration of 7-hydroxycoumarin-glucuronide, over time, of less than 10%.

The UDPGTs are a family of closely related membrane-bound enzymes that are responsible for the transfer of the glucuronyl group from UDPGA to many endogenous and exogenous molecules having functional groups of oxygen, nitrogen, sulfur, and carbon. The liver has been identified as the most important site of glucuronidation, both qualitatively and quantitatively. Other tissues are also known to possess glucuronyl transferase activity.<sup>1</sup> Glucuronidation is a major detoxification pathway, and it functions in rendering xenobiotics more water soluble, which makes them more readily excreted in the urine.<sup>2</sup> Some glucuronides are now known to have clinical relevance,<sup>2</sup> and epirubicin-glucuronide has been investigated as a prodrug for specific treatment of cancer.<sup>3</sup> Other glucuronide conjugates are routinely monitored to determine pregnancy.<sup>4,5</sup>

In many plants, 7-hydroxycoumarin (umbelliferone) is present. It is the principal product of Phase I metabolism of coumarin in humans.<sup>6</sup> It has been used in the treatment of high protein edemas<sup>7</sup> and as an anti-cancer agent.<sup>8</sup> It has also been investigated in relation to its inhibitory effect on human malignant cell lines *in vitro*<sup>9</sup> and in inhibiting oncogene-induced transforma-

tion of murine fibroblasts.<sup>10</sup> It is also used as a pH-sensitive fluorescent indicator, in fluorescence-based immunoassays, and as a blood-brain barrier probe.<sup>11</sup> The 7-hydroxycoumarin is converted by UDPGT to 7-hydroxycoumarin-glucuronide (*Figure 1*). Conway et al. have shown that glucuronidation of 7-hydroxycoumarin is threefold greater in the pericentral areas than the periportal areas of the liver.<sup>12</sup> The majority of coumarin administered is excreted as 7-hydroxycoumarin-glucuronide.<sup>13</sup> Any pharmacological role of the glucuronide conjugate has not yet been determined. Casley-Smith has suggested that, due to the active transport shown to exist for glucuronides, it is possible that 7-hydroxycoumarin-glucuronide is transported into the cells. Glucuronidases present in the cell reconvert the glucuronide to the 7-hydroxycoumarin. After it has exerted its pharmacological action, it might then be reglucuronidated before excretion.<sup>7</sup>


CE has been used for the determination of 7-hydroxycoumarin following both *in vivo*<sup>14,15</sup> and *in vitro*<sup>16,17</sup> metabolism of coumarin and for the determination of 7-hydroxycoumarin and 7-hydroxycoumarin-glucuronide in plasma and urine.<sup>15</sup> The method of Bogan et al.<sup>15</sup> for the direct determination of both compounds

## Indexing terms

7-hydroxycoumarin-glucuronide, UDP-glucuronyl transferase, UDP-glucuronic acid

## Abbreviations

UDP, uridine diphosphate; UDPGT, uridine diphosphate glucuronyl transferase; UDPGA, uridine diphosphate glucuronic acid



**FIGURE 1** Glucuronidation of 7-hydroxycoumarin by UDPGT.

in urine and plasma without any sample preparation was applied to the determination of 7-hydroxycoumarin-glucuronide in an *in vitro* metabolic assay. Other researchers have carried out similar studies on glucuronide production with analysis by HPLC.<sup>18–20</sup> However, it was necessary to stop the reaction by precipitating the protein out of solution. A method similar to that of Deasy et al.<sup>16</sup> that did not require sample cleanup would allow the direct determination of the metabolite in real time without any interference with the reaction mixture. CE has also been used for the determination of glucuronides in urine and in Chinese medicines.<sup>21–23</sup>

## Materials and methods

### Chemicals

UDPGA, 7-hydroxycoumarin, magnesium chloride, deoxycholic acid (sodium salt), and D-saccharic acid 1,4-lactone were purchased from Sigma (St. Louis, MO, U.S.A.); 7-hydroxycoumarin-glucuronide was kindly donated by Schaper and Brummer (Salzgitter, Germany). The electrolyte solution was 90% (100 mM phosphate buffer/11 mM deoxycholic acid [sodium salt]):10% acetonitrile (Labskan, Dublin, Ireland). The phosphate buffer was prepared by adding 100 mM  $K_2HPO_4$  and 100 mM  $KH_2PO_4$  (Riedel de-Haen, Hanover, Germany) solutions together to a pH of 7.0. The deoxycholic acid (sodium salt) was prepared in this buffer, and the acetonitrile was then added. The pH remained at 7.0. Stock solutions of electrolyte buffer were prepared and stored at 4 °C until required.

### UDPGT preparation

A bovine liver was obtained and stored at –80 °C until required. The crude protein solution was prepared by the method of Tegmeier et al.<sup>24</sup> The protein solution was stored at –80 °C until required. The protein concentration was determined by the bicinchoninic acid assay (BCA, Pierce Chemical Co., Rockford, IL, U.S.A.) using bovine serum albumin as standard prepared in 50 mM Tris-HCl. The concentration of protein was 4 mg/mL.

### Incubation solution

The incubation solution consisted of eight components (Table 1). The principal components for the production of 7-hydroxycoumarin-glucuronide are 7-hydroxycoumarin, the enzymatic solution containing the UDPGT, and UDPGA. A 1 mg/mL solution of 7-hydroxycoumarin was prepared in 10% ethanol (Merck, Darmstadt, Germany): 90% deionized water. All other solutions were prepared in deionized water. The reaction will not occur without the Tris-HCl buffer. Reactions were carried out in open 2-mL test tubes (Sarstedt Ltd., Wexford, Ireland) at 37 °C. The reaction was initiated by the addition of the protein solution. A sample was immediately removed and analyzed by CE. It was not necessary to add any material to stop the reaction as the application of the 30,000 V separates the components on the reaction mixture, thus stopping the opportunity for further reaction. Samples were removed approximately every 12 min and analyzed immediately. The reaction was repeated four times. Control studies were carried out in the absence of 7-hydroxycoumarin, UDPGA, and enzyme, respectively.

### Standard curve preparation

The 0–1000 µg/mL standards of 7-hydroxycoumarin-glucuronide were prepared in water, and 10 µL was spiked into 40 µL of protein solution and 50 µL of 50 mM Tris-buffer pH 7.4. It was necessary to denature the protein solution to remove any interference of endogenous β-glucuronidase present. This was achieved by boiling the solution for 5 min. Concentrations of 7-hydroxycoumarin-glucuronide produced were de-

Table 1

COMPONENTS IN THE REACTION MIXTURE, INCLUDING STOCK CONCENTRATIONS AND FINAL CONCENTRATIONS IN THE INCUBATION SOLUTION

Component	Stock solution concentration	Volume µL	Final concentration
7-hydroxycoumarin	6.2 mM	200	0.77 mM
Enzyme solution	4 mg/mL	400	1 mg/mL
Magnesium chloride	1 M	10	6.25 mM
Saccharic acid 1,4-lactone	50 mM	200	6.25 mM
UDPGA	10 mM	200	1.25 mM
Absolute ethanol		50	
Tris-HCl (pH 7.4)	1 M	200	125 mM
Deionized water		340	

terminated from a mean standard curve ( $n = 3$ ) of concentration of 7-hydroxycoumarin-glucuronide versus peak area.

#### CE separation


Separation was carried out on a P/ACE System 5500 CE instrument (Beckman Instruments, Fullerton, CA, U.S.A.). The capillary used was a  $57 \times 50 \mu\text{m}$  i.d. untreated silica capillary (Beckman Instruments) with a capillary-to-detector distance of 50 cm. It was conditioned initially each day by 10-min rinses with 0.1 M hydrochloric acid, followed by 0.1 M sodium hydroxide, then deionized water, and finally electrolyte buffer. Between each run, the capillary was rinsed for 0.8 min with 0.1 M NaOH, then for 2.5 min with electrolyte solution. Samples were applied by 10-sec pressurized in-

jections at 0.5 psi. Separation was achieved at 30 kV (rinse time 0.2 min) at 25 °C with detection at 320 nm. Typical running current was 170  $\mu\text{A}$ . The same capillary was used without any deleterious effects on performance or reproducibility during the duration of the study.


#### Results and discussion

The majority of coumarin administered is excreted as 7-hydroxycoumarin-glucuronide, in humans.<sup>14</sup> It is the principal Phase II metabolite and is produced from the main Phase I metabolite 7-hydroxycoumarin (Figure 1). The method utilized for the determination of 7-hydroxycoumarin and 7-hydroxycoumarin-glucuronide in urine and plasma<sup>15</sup> was applied to the determination of 7-hydroxycoumarin-glucuronide in an *in vitro* metabolic assay.

Separation of 7-hydroxycoumarin-glucuronide from endogenous species present in the metabolic matrix and from 7-hydroxycoumarin is achieved in less than 7 min (Figure 2). It is clearly seen in Figure 2 that



**FIGURE 2** CE electropherogram of metabolic solution as outlined in "Materials and methods." It shows an overlay of electropherograms of samples taken at 1 min, 12 min, 47 min, and 82 min, respectively. The peaks are: a) solvent front containing all neutral components; b) magnesium chloride and 7-hydroxycoumarin (shoulder); and c) 7-hydroxycoumarin-glucuronide. Electropherograms for 12 min, 47 min, and 82 min are shown in offset to illustrate the increase in peak area and are displayed between 5.5 min and 7.5 min only. The remainder of the electropherogram was typical of the 1-min profile.



**FIGURE 3** A plot of time (min) versus mean 7-hydroxycoumarin-glucuronide concentration ( $n = 4$ ) ( $\mu\text{mol/mL/mg}$  protein) from incubation assay study. The equation of the line is  $y = -0.00032 + 0.00309x$  with an  $r^2 = 0.99348$ .

at 1 min no 7-hydroxycoumarin-glucuronide was present, but after 12 min, the UDPGT had already started to produce 7-hydroxycoumarin-glucuronide. At 47 and 82 min, there was a visible increase in the 7-hydroxycoumarin-glucuronide (peak c) content in the matrix. The reaction proceeded in a linear manner for the first 70 min (Figure 3). The mean rate of reaction for the first 70 min was found to be  $3.09 \pm 0.13$  nmol of glucuronide produced per minute per mL of solution per mg of protein ( $n = 4$ ). After 70 min (results not shown), the enzyme efficiency slows down, and after 180 min, no more 7-hydroxycoumarin-glucuronide is formed. The reaction rate was slowed due to substrate limitation, enzymatic deactivation,  $\beta$ -glucuronidase deconjugation, or a combination of the factors.

In the absence of enzyme, 7-hydroxycoumarin, or UDPGA, no 7-hydroxycoumarin-glucuronide was produced. It was possible to monitor the breakdown of the glucuronide conjugate over time to 7-hydroxycoumarin, when the undenatured protein solution was used as the matrix for the standards. The limit of detection for 7-hydroxycoumarin-glucuronide was  $2 \mu\text{g/mL}$  with a linear range of  $0\text{--}100 \mu\text{g/mL}$ . Percentage relative standard deviations for each standard peak area were all below 10%.

### Conclusion

The CE method developed was found to be very fast and reliable for the direct determination of 7-hydroxycoumarin-glucuronide as the *in vitro* metabolite of 7-hydroxycoumarin and UDPGA by the enzymatic action of UDPGT. The method was reproducible with excellent precision and accuracy. No sample cleanup was necessary, and injection of the neat mixture onto the capillary allows results to be obtained in nearly real time without any interference from errors due to sample preparation (extraction steps, precipitation steps, etc.). The method would be ideal for the investigation of UDPGT inhibitors or promoters. Thus, CE has been demonstrated to be applicable to the *in vitro* determination of both Phase I and Phase II metabolism studies of coumarin.

### Acknowledgments

The authors would like to thank Schaper and Brummer, the Coumarin Research Fund, the Research and Postgraduate Studies Committee, Dublin City University, and Forbairt for financial support. We would also like to thank Kepak (Ireland) and Professor Malcolm R. Smyth (Dublin City University) for their help.

©Copyright 1995, ISC Technical Publications, Inc.  
Manuscript received July 20, 1995.

### References

- Clarke DJ, Burchell B. The uridine diphosphate glucuronosyltransferase multigene family. In: Kaufmann FC, ed. Conjugation-deconjugation reactions in drug metabolism and toxicity. Heidelberg:

- Springer-Verlag, 1994:3–29.
- Olson JA, Moon RC, Anders MW, Fenselau C, Shane B. Enhancement of biological activity by conjugation reactions. *J Nutrition* 1992; 122 (3):615–24.
- Haisma HJ, Boven E, van Muijen M, de Jong J, van der Vijgh WJF, Pinedo HM. A monoclonal antibody- $\beta$ -glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer. *Br J Cancer* 1992; 66:474–8.
- Stabenfeldt GH, Daels PF, Munro CJ, Kindahl H, Hughes FP, Lasley B. An oestrogen conjugate enzyme immunoassay for monitoring pregnancy in the mare: limitations of the assay between days 40 and 70 of gestation. *J Reprod Fert Suppl* 1991; 44:37–44.
- Mitsuma M, Yoshimura S, Kambegawa A, Okinaga S, Arai K. Development of a direct microplate enzyme immunoassay for the determination of pregnanediol  $3\alpha$ -glucuronide in urine. *J Steroid Biochem* 1989; 32(3):467–71.
- Egan D, O'Kennedy R, Moran E, Cox D, Prosser E, Thornes RD. The pharmacology, metabolism, analysis and applications of coumarin and coumarin-related compounds. *Drug Metab Rev* 1990; 22(5):503–29.
- Casley-Smith JR, Casley-Smith JR. Chap. 9, Pharmacokinetic considerations of the benzo-pyrones. High protein-oedemas and the benzo-pyrones. Sydney: J.B. Lippincott Co., 1986:417–46.
- Marshall ME, Mohler JL, Edmonds K, et al. An updated review of the clinical development of coumarin (1,2-benzopyrone) and 7-hydroxycoumarin. *J Cancer Res Clin Oncol* 1994; 120(suppl):S39–42.
- Marshall ME, Kervin K, Benefield C, et al. Growth-inhibitory effects of coumarin (1,2-benzopyrone) and 7-hydroxycoumarin on human malignant cell lines *in vitro*. *J Cancer Res Clin Oncol* 1994; 120:S3–10.
- Seliger B, Pettersson H. 7-hydroxycoumarin inhibits oncogene-induced transformation of murine fibroblasts. *J Cancer Res Clin Oncol* 1994; 120(suppl):S23–7.
- Budavari S, ed. The Merck index. Eleventh ed. Rahway, NJ: Merck & Co. Inc., 1989.
- Conway JG, Kauffman FC, Tsukada T, Thurman RG. Glucuronidation of 7-hydroxycoumarin in periportal and pericentral regions of the liver. *Molecular Pharm* 1984; 25:487–93.
- Egan D, O'Kennedy R. Rapid and sensitive determination of coumarin and 7-hydroxycoumarin and its glucuronide conjugate in urine and plasma by high performance liquid chromatography. *J Chromatogr* 1993; 582:137–43.
- Bogan DP, Deasy B, O'Kennedy R, Smyth MR, Fuhr U. Determination of free and total 7-hydroxycoumarin in urine and serum by capillary electrophoresis. *J Chromatogr B* 1995; 663:371–8.
- Bogan DP, O'Kennedy R, Thornes RD, Tegmeier M, Shafer EA. The direct determination of 7-hydroxycoumarin and 7-hydroxycoumarin-glucuronide, in urine and plasma, by capillary electrophoresis. *Analyst*. Submitted 1995.
- Deasy B, Bogan DP, Smyth MR, O'Kennedy R, Fuhr U. Study of coumarin metabolism by human liver microsomes using capillary electrophoresis. *Anal Chim Acta* 1995; 310:101–7.
- Bogan DP, Deasy B, O'Kennedy R, Smyth MR. The use of capillary electrophoresis for studying interspecies differences in coumarin metabolism in liver microsomes. *Xenobiotica*. Submitted 1995.
- Knight BI, Skellern GG. Determination of UDP glucuronosyltransferase activity by measurement of the formation of paracetamol and 4-nitrophenol glucuronides *in vitro* by ion-pair high performance liquid chromatography. *J Chromatogr* 1980; 192(1):247–9.
- To ECA, Wells PG. Rapid and sensitive assays using high performance liquid chromatography to measure the activities of phase II drug metabolising enzymes: glucuronyl transferase and sulpho-transferase. *J Chromatogr* 1984; 301(1):282–7.
- Nakaoka M, Hakusui H. Measurement of the formation of a thioglucuronide, a metabolite of malotilate, in rat hepatic microsomes by high performance liquid chromatography. *J Chromatogr B* 1990; 91:254–9.

21. Liu YM, Sheu SJ. Capillary electrophoresis determination of baicalein, baicalin, wogonin, and wogonin-7-O-glucuronide in traditional Chinese medicinal preparations. *J High Resolut Chromatogr* 1994; 17(7):559-60.
22. Liu YM, Sheu SJ. Determination of the six major flavanoids in *Scutellariae Radix* by micellar electrokinetic capillary electrophoresis. *Anal Chim Acta* 1994; 288(3):221-6.
23. Wernly P, Thormann W, Bourquin D, Brenneisen R. Determination of morphine 3-glucuronide in human urine by capillary zone electrophoresis and micellar electrokinetic capillary chromatography. *J Chromatogr B* 1993; 127:305-10.
24. Tegtmeier F, Belsner K, Brunner G. Enzymatic syntheses of glucuronides using lipophilic hollow fibre membranes. *Bioprocess Eng* 1988; 3:43-7.